Clinical Trial Update: A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluates PRT2527 as a standalone therapy and in combination with zanubrutinib or venetoclax for relapsed/refractory hematologic malign…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive B-cell Non-hodgkin Lymphoma
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Richter Syndrome
• Small Lymphocytic Lymphoma
• T-cell Lymphoma

Drugs mentioned

• PRT2527 (PRT2527)
• Venetoclax (venetoclax)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Prelude Therapeutics | Conditions: Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | Phase 1 | Status: COMPLETED